# Interleukin-6 Antagonists in Critically-ill Covid-19 Patients

> **NCT05218369** · — · UNKNOWN · sponsor: **University of Pecs** · enrollment: 30 (estimated)

## Conditions studied

- COVID-19
- Critical Illness

## Interventions

- **DRUG:** IL6 Antagonist

## Key facts

- **NCT ID:** NCT05218369
- **Lead sponsor:** University of Pecs
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-06
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218369, "Interleukin-6 Antagonists in Critically-ill Covid-19 Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05218369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*